Literature DB >> 25322844

The safety of sulfonylurea therapy in type 2 diabetes: have we reached the practical limits of our evidence base?

Jeffrey A Johnson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25322844     DOI： 10.1007/s00125-014-3417-3

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  8 in total

1.  The philosophical limits of evidence-based medicine.

Authors:  M R Tonelli
Journal:  Acad Med       Date:  1998-12       Impact factor: 6.893

2.  A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results.

Authors:  C L Meinert; G L Knatterud; T E Prout; C R Klimt
Journal:  Diabetes       Date:  1970       Impact factor: 9.461

Review 3.  Variations in tissue selectivity amongst insulin secretagogues: a systematic review.

Authors:  A S Abdelmoneim; S E Hasenbank; J M Seubert; D R Brocks; P E Light; S H Simpson
Journal:  Diabetes Obes Metab       Date:  2011-11-03       Impact factor: 6.577

4.  The UGDP controversy: thirty-four years of contentious ambiguity laid to rest.

Authors:  Theodore B Schwartz; Curtis L Meinert
Journal:  Perspect Biol Med       Date:  2004       Impact factor: 1.416

5.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

Review 6.  SGLT2 inhibitors in the treatment of type 2 diabetes.

Authors:  Farhad M Hasan; Mazen Alsahli; John E Gerich
Journal:  Diabetes Res Clin Pract       Date:  2014-03-11       Impact factor: 5.602

7.  Sulfonylurea in combination with insulin is associated with increased mortality compared with a combination of insulin and metformin in a retrospective Danish nationwide study.

Authors:  Ulrik M Mogensen; Charlotte Andersson; Emil L Fosbøl; Tina K Schramm; Allan Vaag; Nikolai M Scheller; Christian Torp-Pedersen; Gunnar Gislason; Lars Køber
Journal:  Diabetologia       Date:  2014-09-10       Impact factor: 10.122

8.  Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE).

Authors:  David M Nathan; John B Buse; Steven E Kahn; Heidi Krause-Steinrauf; Mary E Larkin; Myrlene Staten; Deborah Wexler; John M Lachin
Journal:  Diabetes Care       Date:  2013-05-20       Impact factor: 19.112
  8 in total
  1 in total

Review 1.  Should Side Effects Influence the Selection of Antidiabetic Therapies in Type 2 Diabetes?

Authors:  George Grunberger
Journal:  Curr Diab Rep       Date:  2017-04       Impact factor: 4.810
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.